【Abstract】Objective To investigate the correlation between the level of peripheral blood circulating tumor cells (CTCs) and pathological parameters and prognosis in patients undergoing radical resection of pancreatic cancer. Methods 98 patients underwent radical resection of pancreatic cancer in our hospital from March 2017 to March 2018 were selected. Another 35 healthy volunteers admitted to our hospital for physical examination at the same time were selected as control group. 7.5 ml peripheral blood was collected, and the level of CTCs was detected by immunomagnetic negative enrichment and immunofluorescence in situ hybridization. The correlation between level of peripheral blood CTCs and pathological features was analyzed among patients with pancreatic cancer. The survival time of patients with positive and negative peripheral blood CTCs was compared by KaplanMeier survival analysis. Multivariate analysis of prognosis was performed by COX proportional hazard model. Results The positive detection rate of CTCs in peripheral blood of patients with pancreatic cancer was 6327% (62/98), the number of detection was 027 with an average of 2.01/ml, and no positive CTCs were detected in control group. Logistic regression analysis showed that lymph node metastasis and envelope invasion were independent risk factors for positive peripheral blood CTCs (P＜005). KaplanMeier survival analysis showed that the 1year survival rate and median survival time were 16133% and 245d among patients with positive CTCs, and were 4722% and 352d among patients with negative CTCs (P=00004). COX regression analysis showed that positive CTCs and lymph node metastasis were independent risk factors for poor prognosis (P＜005). ConclusionThe detection rate of CTCs in peripheral blood is higher among patients with pancreatic cancer, and its level is related to pathological features such as lymph node metastasis. It also has a certain predictive effect on prognosis. Detection of peripheral blood CTCs has guiding significance in the treatment of pancreatic cancer.